<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>75</patient-age><report-id>PHHY2012CA040499</report-id><gender>male</gender><reactions><reaction>Bleeding in bladder</reaction><reaction>Cancer in bladder</reaction><reaction>Second primary malignancy</reaction><reaction>Cancer in stomach</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>ZOMETA</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Prostate cancer metastatic</indication></indications><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Canada</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053169_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134150</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2012CA040499</safetyreportid>
		<primarysourcecountry>CA</primarysourcecountry>
		<occurcountry>CA</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-05-10</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-06</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012CA040499</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>JM</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19360624</patientbirthdate>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Surgery</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bone neoplasm malignant</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Bleeding in bladder</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Urinary bladder bleeding</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Urinary bladder haemorrhage</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Cancer in bladder</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Bladder cancer</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Bladder cancer</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Second primary malignancy</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Second primary malignancy</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Second primary malignancy</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Cancer in stomach</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Stomach cancer</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Gastric cancer</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Cancer in stomach</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Second primary malignancy</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Second primary malignancy</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ZOMETA</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>4</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>4 mg, every 3 onths</drugdosagetext>
				<drugdosageform normalized="solution for injection">Solution For Injection</drugdosageform>
				<drugadministrationroute code="042">Intravenous (not otherwise specified)</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Prostate cancer metastatic</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2010-08-10</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-10-03</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Bladder cancer</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Bladder cancer</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Gastric cancer</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Gastric cancer</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Second primary malignancy</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Second primary malignancy</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urinary bladder haemorrhage</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urinary bladder haemorrhage</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012CA040499, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from a consumer via marketing program (ACCESS <Semaphore x="1385161" class="Medicine" value="Zometa" score="0.93" ID="242959">Zometa</Semaphore>) received on 10 May 2012 with follow up information from a consumer (patient’s daughter) received on 06 Dec 2012. This report refers to an <Semaphore x="2923190" class="MedDRA LLT" value="Elderly" score="1.00" ID="10014348">elderly </Semaphore>male patient (patient ID NC0005CC). The patient's medical history included <Semaphore x="2152114" class="Disease or Finding" value="Malignant Bone Neoplasm" score="1.00" ID="C4016">cancer in his <Semaphore x="1619584" class="AnatomicStructure" value="Bone" score="1.00" ID="C12366">bone</Semaphore></Semaphore>. The patient received <Semaphore x="1385161" class="Medicine" value="Zometa" score="0.93" ID="242959">Zometa </Semaphore>(zoledronate) for <Semaphore x="2430024" class="Disease or Finding" value="Prostate Carcinoma" score="1.00" ID="C4863">the <Semaphore x="1673867" class="Procedure" value="Cancer Therapeutic Procedure" score="1.00" ID="C16212">treatment <Semaphore x="3207273" class="MedDRA LLT" value="Prostate cancer" score="1.00" ID="10060862"><Semaphore x="2430024" class="Disease or Finding" value="Prostate Carcinoma" score="1.00" ID="C4863">of <Semaphore x="2429227" class="Disease or Finding" value="Prostate Carcinoma by AJCC v6 Stage" score="1.00" ID="C90521">prostate cancer </Semaphore></Semaphore>
       <Semaphore x="3108003" class="MedDRA LLT" value="Metastases to prostate" score="1.00" ID="10051678">
        </Semaphore></Semaphore>
      <Semaphore x="3108003" class="MedDRA LLT" value="Metastases to prostate" score="1.00" ID="10051678">
       </Semaphore></Semaphore>
     <Semaphore x="3108003" class="MedDRA LLT" value="Metastases to prostate" score="1.00" ID="10051678">
      </Semaphore></Semaphore>
    <Semaphore x="3108003" class="MedDRA LLT" value="Metastases to prostate" score="1.00" ID="10051678">
     <Semaphore x="2223589" class="Disease or Finding" value="Metastatic Malignant Neoplasm to the Prostate" score="1.00" ID="C7080">and <Semaphore x="2152114" class="Disease or Finding" value="Malignant Bone Neoplasm" score="1.00" ID="C4016"><Semaphore x="3108419" class="MedDRA LLT" value="Metastasis" score="1.00" ID="10062194">metastases </Semaphore>to </Semaphore></Semaphore>
     <Semaphore x="3107233" class="MedDRA LLT" value="Metastases to bone" score="1.00" ID="10027452">
      <Semaphore x="2222549" class="Disease or Finding" value="Metastatic Malignant Neoplasm to the Bone" score="1.00" ID="C3580">
       </Semaphore></Semaphore></Semaphore>
    <Semaphore x="3107233" class="MedDRA LLT" value="Metastases to bone" score="1.00" ID="10027452">
     <Semaphore x="2222549" class="Disease or Finding" value="Metastatic Malignant Neoplasm to the Bone" score="1.00" ID="C3580">
      <Semaphore x="1619584" class="AnatomicStructure" value="Bone" score="1.00" ID="C12366">bone </Semaphore></Semaphore></Semaphore>from 10 Aug 2010 at a dose of 4 mg every 3 months, intravenously. After starting the suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>the patient was hospitalized for about 4 to 5 weeks. The reporter stated that the patient had presence of <Semaphore x="2988829" class="MedDRA LLT" value="Haemorrhage" score="1.00" ID="10055798">bleeding </Semaphore>in his <Semaphore x="1602068" class="AnatomicStructure" value="Bladder Tissue" score="1.00" ID="C32209">bladder </Semaphore>and had to have <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery</Semaphore>. The <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore>was not successful and the patient had to remain longer in the hospital. He had still presented <Semaphore x="2429227" class="Disease or Finding" value="Prostate Carcinoma by AJCC v6 Stage" score="1.00" ID="C90521"><Semaphore x="1595965" class="Disease or Finding" value="Bladder Cancer cM0 TNM Finding v7" score="1.00" ID="C89364">cancer in bladder</Semaphore>, prostate </Semaphore>and <Semaphore x="2586114" class="AnatomicStructure" value="Stomach" score="1.00" ID="C12391">stomach</Semaphore>. Then, the reporter informed that the patient was not using <Semaphore x="1385161" class="Medicine" value="Zometa" score="0.93" ID="242959">Zometa </Semaphore>lately since “he was in his last few days”. <Semaphore x="2394286" class="Procedure" value="Pharmacotherapy" score="1.00" ID="C15986">Treatment with <Semaphore x="1385161" class="Medicine" value="Zometa" score="0.93" ID="242959">Zometa </Semaphore>medication </Semaphore>was stopped on 03 Oct 2012. The event <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>and causality were not reported.Follow up information from a consumer (patient’s daughter) received on 06 Dec 2012: Updated medication details and action taken.</narrativeincludeclinical>
				<sendercomment>MAC: Based on available information, a causal role of Zometa for urinary bladder bleeding could not be ruled out. Patient with one malignancy are prone to develop second malignancies and therefore, bladder cancer and gastric cancer are considered not suspected to Zometa.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>